Exosome Cargo Loading & Drug Delivery Development
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
At Creative BioMart Microbe, we provide comprehensive cargo loading and drug delivery development services purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), cytoplasmic membrane vesicles (CMVs) from Gram-positive bacteria, and fungal EVs. Our platform integrates exogenous cargo loading via electroporation, sonication, and co-incubation; endogenous loading through genetic engineering of cargo-secretion fusion proteins; loading efficiency quantification; surface engineering for targeting ligand display; stability optimization for in vivo delivery; and preclinical drug delivery validation into a single, milestone-driven workflow that transforms empty microbial vesicles into functional theranostic nanocarriers.
Unlike generic extracellular vesicle engineering CROs that apply mammalian exosome loading protocols to microbial vesicles without adaptation, we have optimized every loading condition, cargo compatibility assessment, and surface modification strategy for the unique membrane composition, lumen architecture, and biogenesis mechanisms of microbial vesicles. From loading protocol development to in vivo delivery validation, clients receive quantified loading efficiency data, characterized drug-loaded vesicle batches, and validated delivery performance that supports CMC documentation, IND-enabling packages, and product development milestones. Contact us to discuss your specific cargo loading and drug delivery requirements.
Figure 1. Schematic overview of the integrated cargo loading and drug delivery development platform for microbial extracellular vesicles, spanning exogenous loading methods, endogenous genetic engineering, loading efficiency quantification, surface targeting engineering, stability optimization, and preclinical delivery validation.
Services
Service Workflow
Service Details
Exosome Drug Loading Process Development
We provide drug loading process development services for microbial vesicles, covering method selection across electroporation, sonication, passive co-incubation, and genetically encoded loading strategies. Our capabilities include loading condition screening across parameter gradient matrices, optimization of the balance between loading efficiency and vesicle integrity, and compatibility assessment for nucleic acids, proteins, peptides, and small molecules. Clients receive loading method recommendations, optimized protocols, and loading efficiency data that support rapid candidate screening and downstream process scale-up.
Endogenous Loading via Genetic Engineering of Cargo-Secretion Fusion
We provide endogenous loading services through genetic engineering of microbial strains to express cargo-secretion fusion constructs. Our capabilities include vesicle-sorting signal selection for OMV and CMV biogenesis pathways, plasmid-based and chromosomal integration strategies, secretion pathway optimization, and loading validation by proteomic and functional assays. Clients receive genetically encoded, self-loading vesicle production strains with validated cargo enrichment and confirmed functional activity, suitable for scalable manufacturing development.
Exosome Drug Release Kinetics Analysis
We provide drug release kinetics analysis services for loaded vesicles under physiologically relevant conditions, including buffer, serum-containing media, and pH- or temperature-stressed environments. Our capabilities include release curve generation using dialysis, ultrafiltration, or flow-through sampling, cargo quantification by fluorescence, HPLC, or bioassay, and kinetic modeling to distinguish burst release from sustained release behavior. Comparative profiling across loading methods, formulations, and surface modifications identifies the parameters governing cargo retention. Clients receive release kinetics reports that support formulation selection, stability assessment, and CMC documentation.
Surface Engineering & Targeting Ligand Display
We provide surface engineering services to transform generic mEVs into targeted nanocarriers with enhanced delivery specificity. Our capabilities include genetic surface display of targeting ligands and stealth coatings, chemical conjugation of functional moieties, PEGylation for circulation enhancement, and stimuli-responsive release modifications. Clients receive surface-engineered vesicles with validated ligand display efficiency, confirmed targeted cellular uptake enhancement, and improved therapeutic index compared to unmodified carriers.
Stability Optimization & In Vivo Delivery Validation
We provide stability optimization and in vivo delivery validation services for drug-loaded vesicle formulations. Our capabilities include accelerated stability testing under multiple temperature and pH conditions, freeze-thaw resilience assessment, serum stability evaluation, simulated gastrointestinal fluid exposure, cryoprotectant and formulation screening, and lyophilization cycle development. In vivo delivery validation includes biodistribution imaging, tissue drug concentration quantification, and carrier-mediated delivery confirmation. Clients receive formulation recommendations, stability profiles, and preclinical proof-of-concept delivery data.
Service Specifications & QC Standards
Instrumentation & Capability
- Electroporation: Square-wave electroporation systems with parameter optimization for vesicle membrane permeabilization.
- Sonication: Probe and bath sonication systems for acoustic loading of small molecules and peptides.
- Nanoparticle Tracking Analysis: Real-time particle concentration and size distribution analysis before and after loading.
- HPLC-MS/MS: High-performance liquid chromatography coupled with mass spectrometry for small-molecule cargo quantification.
- UV-Vis/Fluorescence: Spectrophotometric and fluorometric detection systems for cargo concentration and loading efficiency determination.
- Flow Cytometry: Multi-parameter flow cytometry for surface display quantification and targeted cellular uptake validation.
- In Vivo Imaging: Whole-body fluorescent and bioluminescent imaging for drug-loaded vesicle biodistribution tracking.
- Genetic Engineering: CRISPR-based genome editing and recombination systems for endogenous cargo loading strain development.
Typical Data Range
- Loading efficiency varies by cargo type, loading method, and microbial strain; we provide project-specific optimization and quantification for each parameter.
- Cargo retention and stability depend on molecular properties, loading method, and formulation; we optimize storage conditions and provide project-specific stability data.
- Surface display efficiency depends on anchor protein, ligand size, and detection method; we quantify ligand density for each engineered construct.
- In vivo targeting performance varies by ligand, route of administration, and target tissue; we validate tissue-specific delivery for each targeting strategy.
Turnaround Time
| Project Type |
Timeline |
| Exogenous loading method screening (3 methods × 3 conditions) |
2–3 weeks |
| Endogenous genetic strain construction and validation |
4–6 weeks |
| Loading efficiency optimization |
2–3 weeks |
| Drug-loaded vesicle characterization package |
1–2 weeks |
| Surface engineering (genetic or chemical) |
3–4 weeks |
| Stability optimization and formulation development |
3–5 weeks |
| In vivo delivery validation (single route, n=15) |
4–6 weeks |
| Integrated drug delivery development package |
10–16 weeks |
| Expedited timeline |
+50% fee, 40% time reduction |
Timeline may vary based on cargo type, loading method, and in vivo model complexity.
Deliverables
- Exogenous loading report: Parameter optimization matrix, loading efficiency comparison, vesicle integrity data.
- Endogenous loading report: Genetic construct maps, expression validation, cargo enrichment quantification, strain stability.
- Loading efficiency report: Cargo-to-particle ratio, copy number per vesicle, release kinetics, batch consistency data.
- Surface engineering report: Ligand display quantification, targeted uptake enhancement, PEGylation efficiency.
- Stability report: Accelerated degradation curves, freeze-thaw resilience, serum stability, GI fluid exposure data.
- In vivo delivery report: Biodistribution imaging, tissue drug concentration, PK parameters, target-to-liver ratio.
Quality Control
- Pre-loading test article: NTA, DLS, protein content, endotoxin (LAL), sterility on every batch.
- Post-loading QC: NTA/DLS for size distribution, zeta potential, TEM for morphology, endotoxin re-test.
- Loaded cargo QC: Concentration by HPLC/UV-Vis/fluorescence, activity by bioassay (if applicable), purity by SDS-PAGE.
- Release kinetics: Dialysis or ultrafiltration over 72 h with sampling at 0, 2, 4, 8, 24, 48, 72 h.
- Batch consistency: Loading efficiency assessed across three independent batches for reproducibility.
- Characterization aligned with MISEV2023 minimal requirements for extracellular vesicle studies.
Sample Requirements
| Required Information |
Optional Information |
Not Accepted |
- Cargo identity (drug name, CAS, sequence, or structural formula)
- Cargo molecular weight and physicochemical properties
- Cargo solubility data (aqueous, DMSO, organic)
- Cargo concentration or amount available
- mEV type (OMVs, CMVs, fungal EVs, phage vesicles)
- Purified vesicle suspension with NTA concentration
- Intended administration route (IV, oral, topical, intranasal)
- Target tissue or cell type
|
- Prior loading attempts or published methods
- Target loading efficiency or copy number per vesicle
- Release kinetics requirements (immediate vs. sustained)
- Targeting ligand preference (if surface engineering needed)
- Stability requirements (storage temperature, shelf life)
- Regulatory documentation needs
|
- Cargoes in organic solvents without prior discussion
- Cargoes with documented vesicle membrane disruption activity
- Uncharacterized or impure cargo preparations
- Highly toxic cargoes without safety documentation
- Radioactive or biohazardous cargoes without proper permits
- mEVs with endotoxin levels exceeding project-specific safety thresholds
|
Recommended Sample Quantity by Service:
| Service |
Cargo Amount |
mEV Amount |
| Exogenous loading screening |
1–5 mg |
1–2 mg total protein |
| Endogenous strain construction |
Expression plasmid or gene sequence |
N/A (strain generated in-house) |
| Loading efficiency optimization |
5–10 mg |
2–5 mg total protein |
| Surface engineering |
Ligand peptide/protein (1–5 mg) |
1–2 mg total protein |
| Stability optimization |
10–20 mg |
5–10 mg total protein |
| In vivo delivery validation |
20–50 mg |
10–20 mg total protein |
Storage & Shipping: Ship purified vesicle suspensions on dry ice (–80°C) with cold-chain documentation. Cargo should be shipped according to its specific stability requirements (typically –20°C for small molecules, –80°C for nucleic acids and proteins). Provide certificate of analysis, SDS, and safety data sheet (SDS) for the cargo. For endogenous loading projects, provide the expression construct or gene sequence with restriction enzyme map.
Our Advantages
- mEV-Optimized Loading Methods: Our electroporation, sonication, and co-incubation protocols are specifically calibrated for microbial vesicle membranes, which differ fundamentally from mammalian exosomes in lipid composition, membrane rigidity, and lumen pH, ensuring higher loading efficiency and better cargo retention.
- Dual Loading Strategy: We offer both exogenous loading (rapid, flexible, compatible with any cargo) and endogenous genetic loading (stable, scalable, self-assembling production strains), enabling clients to select the optimal approach for their development stage and cargo properties.
- Integrated Surface Engineering: Our genetic and chemical surface modification capabilities transform drug-loaded vesicles into targeted delivery systems with enhanced tissue specificity, reduced off-target accumulation, and improved therapeutic index compared to unmodified carriers.
- End-to-End Delivery Validation: From loading protocol development through stability optimization to in vivo biodistribution and target tissue drug concentration, we provide a complete chain of evidence that connects formulation characteristics to delivery performance.
- Regulatory-Ready Documentation: Loading efficiency quantification, batch characterization, release kinetics, and stability data are prepared in formats suitable for CMC packages, IND-enabling submissions, and product specifications.
Applications
siRNA/mRNA Therapeutic Delivery via OMV Carriers
Electroporation-loaded nucleic acids delivered by engineered OMVs enable gene therapy and RNA interference applications.
Small-Molecule Chemotherapy Loading & Targeted Delivery
Lipophilic drug loading and surface targeting transform mEVs into precision chemotherapy nanocarriers.
Protein/Enzyme Cargo Delivery for Therapeutics
Endogenous loading of therapeutic proteins and enzymes into vesicles via genetic engineering enables sustained delivery.
Oral Vaccine Antigen Delivery via mEV Platform
Engineered mEVs with displayed antigens and loaded adjuvants enable oral mucosal vaccine delivery.
Case Study
Case Study: Engineered Bacterial Outer Membrane Vesicles Encapsulating Oncolytic Adenoviruses for Cancer Virotherapy
Researchers developed an engineered bacterial outer membrane vesicle (OMV) system that encapsulates oncolytic adenoviruses (Ads) within a bio-mineralized calcium phosphate (CaP) shell, creating a microbial nanocomposite for enhanced cancer virotherapy. The CaP shell shields OMV surface antigens to reduce immune clearance and prolong circulation, while the OMVs serve as natural immunoadjuvants that remodel the tumor microenvironment.
Upon tumor cell entry, the embedded pyranose oxidase (P2O) catalyzes glucose to produce excess hydrogen peroxide, triggering tumor autophagy that promotes Ads replication through a positive feedback loop. In female mouse tumor models, the OMVs@P2O-Ads nanocomposite significantly inhibited tumor growth compared to free Ads or unencapsulated OMVs. This study demonstrates how engineered microbial vesicles can be transformed into sophisticated therapeutic delivery vehicles through combined cargo loading, surface shielding, and functional enzyme integration, establishing a paradigm for mEV-based combination cancer therapy.
Figure 2. Preparation and in vivo evaluation of the biomineralized microbial nanocomposite. (Ban, et al. 2023)
FAQs
Q: What types of cargo can be loaded into microbial vesicles?
A: We have successfully loaded small molecules (doxorubicin, paclitaxel, curcumin), nucleic acids (siRNA, mRNA, plasmid DNA, miRNA), proteins (enzymes, antibodies, cytokines), peptides (cell-penetrating peptides, targeting ligands), and nanoparticles (gold, iron oxide) into bacterial OMVs, probiotic CMVs, and fungal EVs. Cargo compatibility depends on molecular weight, charge, hydrophobicity, and stability.
Q: What is the difference between exogenous and endogenous loading?
A: Exogenous loading loads pre-formed therapeutic cargo into purified vesicles using electroporation, sonication, or passive incubation. It is rapid (days to weeks), flexible for any cargo, and suitable for early-stage screening. Endogenous loading engineers the production strain to express cargo fused to vesicle-sorting signals, so cargo is packaged during vesicle biogenesis. It is slower (weeks to months) but enables stable, scalable production of self-loading strains ideal for manufacturing.
Q: How is loading efficiency calculated?
A: Loading efficiency is calculated as the percentage of input cargo recovered inside vesicles after purification, typically measured by comparing cargo concentration in the post-loading supernatant to the pre-loading input. We also report cargo-to-particle ratio (molecules or mass per vesicle), copy number per particle (for nucleic acids), and enrichment fold relative to background protein. All methods are validated against calibration curves with appropriate controls.
Q: Can you load multiple cargoes simultaneously?
A: Yes. We offer co-loading of multiple therapeutic agents, such as siRNA + small-molecule drug combinations for synergistic therapy, or antigen + adjuvant combinations for vaccine applications. Co-loading strategies include sequential loading (one cargo at a time with intermediate purification), simultaneous loading (both cargoes in a single step), and compartmentalized loading (one cargo in the lumen, another on the surface). Compatibility and interaction between cargoes are assessed empirically.
Q: Do drug-loaded vesicles retain cargo during storage?
A: Cargo retention depends on cargo properties, loading method, and storage conditions. We optimize formulation (cryoprotectants, lyophilization, PEGylation) to maximize stability and provide project-specific accelerated stability data as part of the service.
Q: Can you add targeting ligands to drug-loaded vesicles?
A: Yes. We offer both genetic surface display (fusing targeting peptides, scFv, or nanobodies to OmpA, Lpp, or other membrane anchors) and chemical conjugation (NHS-ester or maleimide chemistry) to attach ligands to purified vesicles. Targeting ligands evaluated include RGD/iRGD for tumor targeting, mannose for macrophage targeting, and folate for folate-receptor-positive cells. Targeted uptake enhancement is validated by flow cytometry and confocal microscopy.
Q: What in vivo models do you use for delivery validation?
A: Our standard in vivo delivery validation uses BALB/c or C57BL/6J mice with fluorescent or radiolabeled drug-loaded vesicles administered via the intended clinical route (IV, IP, oral gavage, topical, intranasal). Biodistribution is assessed by IVIS whole-body imaging, tissue fluorescence, and HPLC-MS/MS quantification. Target tissue drug concentration is measured at 1 h, 4 h, 8 h, and 24 h post-dose. Tumor-targeting validation is available in B16-F10 or CT26 syngeneic tumor models.
Q: Is your loading service compatible with GMP manufacturing?
A: Our standard service is research-grade (R&D) with validated methods and comprehensive documentation. For endogenous loading, the engineered production strain can be transferred to GMP manufacturing facilities with full genetic construct documentation and strain bank records. For exogenous loading, process parameters are documented for technology transfer to GMP-compliant manufacturing. Contact us to discuss GMP pathway requirements and process scale-up.
References:
- Ban, W., et al. (2023). Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy. Nature Communications, 14, 2933.
Related Services:
